A structure-function approach to optimizing TLR4 ligands for human vaccines.
Carter D, Fox CB, Day TA, Guderian JA, Liang H, Rolf T, Vergara J, Sagawa ZK, Ireton G, Orr MT, Desbien A, Duthie MS, Coler RN, Reed SG.
Carter D, et al.
Clin Transl Immunology. 2016 Nov 2;5(11):e108. doi: 10.1038/cti.2016.63. eCollection 2016 Nov.
Clin Transl Immunology. 2016.
PMID: 27990284
Free PMC article.
Adjuvants are combined with vaccine antigens to enhance and modify immune responses, and have historically been primarily crude, undefined entities. Introducing toll-like receptor (TLR) ligands has led to a new generation of adjuvants, with TLR4 ligands being …
Adjuvants are combined with vaccine antigens to enhance and modify immune responses, and have historically been primarily crude, undefined e …